About
Oncology Treatments
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (9)
Bryan Kim,DMD|Chief Executive Officer
DMD
Elevar Therapeutics
team_member
Chul-Woong Park, MBA, CPA|Chief Financial Officer & Corporate Secretary
Chief Financial Officer & Corporate Secretary
Elevar Therapeutics
executive
Daneng Li,M.D.|Senior Advisor
M.D.
Elevar Therapeutics
team_member
Dominick DiPaolo|SVP, Quality & Drug Safety
SVP, Quality & Drug Safety
Elevar Therapeutics
team_member
Michael Palucki, PhD|SVP, Manufacturing
SVP, Manufacturing
Elevar Therapeutics
team_member
Mitesh Borad,M.D.|Senior Advisor
M.D.
Elevar Therapeutics
team_member
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
8
As Collaborator
2
Total Enrollment
1,221
By Phase
PHASE2: 2PHASE1: 4PHASE1/PHASE2: 3PHASE3: 1
By Status
COMPLETED: 4TERMINATED: 4WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06308575Collaborator
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
PHASE2Withdrawn
Started: Nov 1, 2024 · Completed: Nov 5, 2024
NCT05287360Lead Sponsor
A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants
PHASE1Completed
60 participants
Started: Dec 30, 2021 · Completed: Mar 24, 2022
NCT04526106Lead Sponsor
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
PHASE1/PHASE2Active, not recruiting
490 participants
Started: Sep 2, 2020 · Completed: Dec 31, 2027
NCT04119453Lead Sponsor
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
PHASE2Terminated
80 participants
Started: Jan 22, 2020 · Completed: Jun 28, 2023
NCT04073615Lead Sponsor
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
PHASE1Terminated
29 participants
Started: Nov 18, 2019 · Completed: May 31, 2023
Locations (1)
Headquarters
Seoul, Korea
Map
Loading map...